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Pharmacological properties of rutin 
and its potential uses for Alzheimer’s 
disease
Abstract: 
Rutin, a flavonoid with a wide range of biological activities, has a long history of use in nutritional 
supplements owing to its action against oxidative stress, inflammation, and hyperglycemia. Because of 
its pharmacological properties such as antioxidant, antiapoptosis, antiinflammation, rutin is proposed 
to treat Alzheimer’s disease (AD). AD is a complex, multi-factorial neurodegenerative disease, and 
is characterized by neuronal atrophy of brain tissue. One of the pathological hallmarks of AD is the 
aggregation of soluble β amyloid (Aβ) into fibrillary deposits. Aβ aggregation induces neurotoxicity, 
oxidative stress and neuro-inflammation. In this review, we discussed the preclinical evidence on the 
antioxidant, antiapoptosis and anti-inflammatory proprieties of rutin, and the application of rutin 
in AD preclinical models. Rutin, delivered via oral and intraperitoneal routes, has been shown to 
functionally modify the cognitive and behavioural symptoms of AD in vivo due to its ability to cross 
the blood-brain barrier and act as both an antioxidant and an anti-inflammatory agent in the brain. 
Rutin attenuates oxidative stress, decreases the production of nitric oxide (NO) and proinflammatory 
cytokine and inhibits Aβ aggregation and cytotoxicity. Further studies to improve its bioavailability 
and investigations into its protective activities in AD would provide a concrete foundation for the use 
of rutin in clinical trials.
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Introduction
Flavonoids, a group of natural substances with diverse phenolic structures, are found in fruits, 
vegetables, roots, grains, bark, flowers, stems, wine and tea [1]. The most common native flavonoid is 
rutin, which is found in a wide variety of plants (>70 plant species) and plant-based products [2, 3]. 
The nonmenclature of rutin varies in the literature and it may be referred to as rutoside, quercetin-
3-O-rutinoside, vitamin P and sophorin.  The etymology of the rutin classification has been linked 
to the Latin name for the rue plants Ruta graveolens, which can be dated back to the 19th century 
when rutin was first isolated. The content of rutin is the highest in leaves of rue plants (86.0 mg/g 
dw) followed by flowers of buckwheat (53.5 mg/g dw), flowers of pansy (33.5 mg/g dw), leaves of 
buckwheat (20.0 mg/g dw), and flowers of rose (10.0 mg/g dw) [4]. Buckwheat has been cultivated 
as a source of rutin for herbal drug preparation in the United States since the mid-20th century and 
nowadays buckwheat plants Fagopyrum are considered to be a major dietary source of rutin.
Chemically, rutin, 2-(3,4-dihyd-roxyphenyl)-5,7-dihydroxy-3-[β-L-rhamnopyranosyl-(16)—β-
D-glucopyranosyloxy]-4H-chromen-4-1, is a glycoside comprising flavonolic aglycone quercetin 
alongside with disaccharide rutinose [Fig.1]. It appears as an odourless yellow crystalline powder that 
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disability for individuals aged 70 years and older, and the seventh 
leading cause of death. There are nearly 10 million new cases every 
year; a number that is projected to grow to 82 million by 2030 and 
152 million by 2050. 
The current treatment strategy for AD is not curative but aims 
to maintain cognitive function, manage behavioural symptoms 
and slow symptom progression. Cholinesterase inhibitors may be 
prescribed for symptom management in mild to moderate AD. 
N-methyl D-aspartate (NMDA) antagonists can be prescribed 
to manage symptoms in moderate to severe AD. Since NMDA 
antagonists have a different mechanism of action to cholinesterase 
inhibitors, both treatments can be prescribed concomitantly. The 
impact of AD on patients, families, carers and wider society coupled 
with the limitations in current pharmacotherapy, which offer 
symptomatic improvement only, highlights a need for investment 
into novel drug targets. Emerging research has identified flavonoids 
as a unique class of therapeutic molecules with potential efficacy 
for AD. Rutin, a naturally occurring flavonoid, has been found 
to exhibit multiple properties (e.g. antioxidant, anti-inflammatory 
and cytoprotective functions) with clinical potential for the 
prevention and treatment of AD [15] and will be the focus of this 
review.
Pharmacological properties of rutin
Rutin as an antioxidant
Reactive oxygen species (ROS) are formed when cells exposed to 
oxygen generate oxygen free radicals. Endogenous free radicals 
are synthesized due to inflammation, mental stress, infection, 
ischemia,  immune cell activation, excessive exercise, cancer, and 
aging while exogenous free radicals are formed due to air and water 
pollution, radiation, alcohol, heavy or transition metals, cigarette 
smoke, cooking, and industrial solvents [16, 17]. Mitochondria 
are the main source of endogenous ROS, but ROS can also occur 
in other organelles [18]. Examples of ROS include free radicals 
(superoxide, O−2), hydroxyl radicals (OH), and non-radicals 
(hydrogen peroxide, H2O2). OH has been recognized as the most 
reactive form of ROS and is thought to be primarily liable for the 
toxic effects of ROS. And O−2 is proposed to play a vital role in 
ROS production [19]. The defense mechanisms of small-molecule 
antioxidants and antioxidant enzymes have been found to decrease 
cellular ROS [20]. Superoxide dismutase (SOD) reduce O−2 into 
the more stable molecule, H2O2. H2O2 may generate OH, which 
is a highly reactive hydroxyl radical and can be reduced by catalase 
(CAT), glutathione peroxidase (GPX), and other peroxidases to 
2
is practically insoluble in H2O and partially soluble in alcohol [5]. 
Since living organisms are unable to synthesise rutin, ingestion of 
dietary sources of rutin is the major mechanism by which rutin is 
obtained in the body [6].  
The IUPAC name of  rutin (rutoside, quercetin-3-O-
rutinoside) is 2-(3,4-dihyd-roxyphenyl)-5,7-dihydroxy-3-[β-
L-rhamnopyranosyl-(1 6)—β-D-glucopyranosyloxy]-4H-
chromen-4-1), and it is classified as a polyphenolic flavonoid.
Rutin has several pharmacological and biological effects, such as 
anti-inflammatory, antioxidant, antihypertensive, antiapoptotic, 
antiautophagic and neuroprotective activities [7]. It has various 
protective effects in vitro as well as in vivo against oxidative stress 
and lipid peroxidation [8]. It attenuates oxidative stress, decreases 
in vitro production of nitric oxide (NO) and proinflammatory 
cytokines, inhibits amyloid β (Aβ) aggregation and cytotoxicity 
[9]. Additionally, this bioflavonoid may have the potential to 
protect the kidneys against ischemia-reperfusion-induced injury 
[10], ameliorate oxidative stress and preserve hepatic and renal 
function after exposure to cadmium and ethanol [11], alleviate 
cisplatin-induced nephrotoxicity in rat, and attenuate gentamicin-
induced renal damage via decreasing oxidative stress, inflammation, 
autophagy, and apoptosis in rodents [12]. It has been proposed 
that rutin can be used for treatment of Alzheimer’s disease (AD) 
[13, 14].
AD is the most common neurodegenerative disease and the most 
common type of dementia. AD patients experience cognitive and 
mental deficits such as memory loss and confusion in addition to 
personality and intellect disorders. AD is the sixth leading cause 
of death in the United States, accounting for 3.6% of all deaths 
in 2014. In the United States alone, approximately 6.08 million 
Americans had either clinical AD or mild cognitive impairment 
due to AD in 2017. Approximately 44 million people in the world 
today suffer from dementia and AD accounts for about 60% of all 
dementia cases. Globally, dementia is the second largest cause of 
Figure 1: Chemical structure of rutin.
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H2O and O2. The cellular antioxidant glutathione (GSH) is 
involved in two types of reactions. First, GSH in its reduced form 
non-enzymatically reacts with O−2 and OH for the elimination 
of ROS. GSH serves as the electron donor for the reduction of 
peroxides in the GPX reaction. When GSH reacts with ROS, 
it is oxidized and forms glutathione disulfide (GSSG) (the last 
product of GPX reactions). GSH can then be restored from GSSG 
by the reaction with glutathione reductase through the transfer 
of electrons from nicotinamide adenine dinucleotide phosphate 
(NADPH) to GSSG [21]. Several studies have indicated that 
GSH is involved in inhibiting DNA damage and apoptotic cell 
death after oxidative stress. Therefore, cellular antioxidants and 
antioxidant enzymes work together to inhibit ROS accumulation 
in the cell. Dysregulation of their functions is an indication of 
altered oxidative states, which may result in cell death.
Several mechanisms have been found to be responsible for 
antioxidant activities of rutin in both in vitro and in vivo models. 
It has been revealed that its chemical structure can scavenge ROS 
directly. Rutin is also alleged to increase the production of GSH, 
and upregulate cellular oxidative defense systems by increasing 
expression of various antioxidant enzymes such as CAT and SOD 
[22]. Additionally, rutin inhibits xanthine oxidase, which is involved 
in ROS generation [23]. It also scavenge ROS by donating hydrogen 
atoms to superoxide anions, peroxy radicals and hydroxyl radicals 
[24]. Research revealed that rutin effectively reduced the level of 
malondialdehyde (MDA), increasing CAT, GPX, SOD, GSH and 
nuclear factor erythroid 2–related factor 2 (Nrf2) levels in colistin-
induced neurotoxicity [25]. Enhanced activity of xanthine and 
NADPH oxidase (NOX), which are the primary cellular enzymes 
responsible for the generation of superoxide radicals, is inhibited 
by rutin. Due to its polyphenolic structure, rutin can scavenge 
free radicals and chelate transition metal ions, which participate 
in Fenton reactions to generate reactive hydroxyl radicals [26, 27].
The main functional groups in the rutin molecule are the hydroxyl 
groups at positions 5 and 7 of the A ring, as well as the double 
bond in the C ring of the quercetin-polyphenolic component, 
which are responsible for its antioxidant activity [28]. Research 
has shown that under pathological conditions such as rheumatoid 
arthritis or cancer, rutin could inhibit the overproduction of 
oxygen radicals by neutrophils [29]. Furthermore, rutin has been 
found to facilitate the degradation of peroxides, including lipid 
peroxides, by regulating the level of GSH and effectively protected 
phospholipids from peroxidation. Several in vivo studies revealed 
that rutin treatment significantly attenuates decrease in the levels 
and activities of GSH and GSH-dependent enzymes (GSH-Px 
and GSSG-R) in rats [30]. In addition, rutin-facilitated regulation 
of the redox balance in fibroblasts and prevented decrease in 
nonenzymatic antioxidants, including vitamins E and C, after UV 
irradiation [31]. Rutin significantly reduced the cisplatin-induced 
oxidative stress by inhibiting lipid peroxidation and increasing 
antioxidant activity [32]. Research revealed that rutin could 
directly scavenge free radicals by chelating metal iron ions [33, 
34]. Collectively, rutin reduces ROS production, NOX activity 
and oxidative products like MDA, thiobarbituric acid reactive 
substance, as well as increases antioxidant status such as SOD, 
GSH, GPX and CAT [35, 36 37, 38, 39, 40 &41].
Rutin as an antiapoptotic
Cell proliferation and elimination are essential in the maintainence 
of homeostasis of the physiological processes of an organism 
[42]. The unwanted cells are removed during the processes of 
pathogenesis, metamorphosis, embryogenesis as well as tissue 
turnover. The mechanisms of apoptosis are highly multifaceted 
and sophisticated, involving an energy-dependent cascade of 
molecular events [Figure 2]. There are two linked apoptotic 
pathways: the extrinsic or death receptor pathway and the intrinsic 
or mitochondrial pathway, where molecules in one pathway can 
influence the other [43]. There is an additional pathway that 
involves T-cell mediated cytotoxicity and perforin-granzyme-
dependent killing of the cell. The perforin/granzyme pathway can 
induce apoptosis via granzyme B or granzyme A. The extrinsic, 
intrinsic, and granzyme B pathways converge on the same terminal, 
or execution pathway, which starts with the cleavage of caspase-3 
and results in DNA fragmentation, degradation of cytoskeletal and 
nuclear proteins, cross-linking of proteins, formation of apoptotic 
bodies, expression of ligands for phagocytic cell receptors and 
finally uptake by phagocytic cells. Caspase-dependent apoptotic 
cell death occurs due to inactivation of survival pathways, like 
PI3K (phosphatidylinositol 3-kinase) /Akt (protein kinase B) 
pathway [44, 45]. Bcl-2 (B-cell lymphoma 2) inhibits intrinsic 
apoptosis by binding to the proapoptotic proteins Bax and Bcl-2 
homologous antagonist/killer (Bak) [46]. The granzyme A pathway 
activates a parallel, caspase-independent cell death pathway via 
single stranded DNA damage [47].
Schematic representation of apoptotic events. There are two main 
pathways of apoptosis; the extrinsic and intrinsic pathways, as well 
as a perforin/granzyme pathway. Each requires specific triggering 
signals to initiate an energy-dependent cascade of molecular 
events. Each pathway activates its own initiator caspase (8, 9, and 
10) leading to caspase-3 activation and initiating the execution 
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pathway. However, granzyme A works in a caspase-independent 
fashion. The execution pathway results in characteristic 
cytomorphological features including cell shrinkage, chromatin 
condensation, formation of cytoplasmic blebs and apoptotic 
bodies and finally phagocytosis of the apoptotic bodies by adjacent 
parenchymal cells, neoplastic cells or macrophages.
Figure 2: Schematic representation of apoptotic events..
Mitogen activated protein kinase (MAPK) is involved in signal 
transduction for apoptosis [48], and its levels indicate if the cell 
survives or dies, as they reveal cell damage [49]. The expression of 
MAPK is upregulated during the process of apoptosis in neurons 
and glial cells after spinal cord injury [50, 51]. Additionally, 
MAPK expression could facilitate the inflammatory response [52]. 
Inactive p38 MAPK is distributed mainly in the cytoplasm, and 
is translocated to the nucleus upon activation to regulate gene 
expression through the phosphorylation of transcription factors 
[53]. Extracellular stimuli, such as inflammatory cytokines, induce 
the phosphorylation and activation of p38 MAPK through a kinase 
cascade [54, 55]. Activated p38 MAPK induces the expression of 
enzymes, such as cyclooxygenase (COX) and inducible nitric oxide 
synthase (iNOS), in addition to numerous inflammatory-related 
molecules, which facilitate the inflammatory response. It has 
been demonstrated that p38 MAPK expression in the spinal cord 
injury model was reduced by rutin thus indicating its protential 
to protect the cells of the spinal cord by lowering pro-apoptotic 
proteins expression [56].  Research revealed that rutin protects 
human dopaminergic cells against rotenone-induced injury by 
inhibiting the p38 MAPK signalling pathway [57].  Rutin also 
significantly protects fibroblasts from ultraviolet (UV)-induced 
apoptosis, particularly in response to UVA, through reduced 
caspase activation and cytochrome c release, as well as increased 
Bcl-2 expression. Additionally, it has been found that decrease of 
caspase-9 and caspase-3 activities are the key to the neuroprotective 
action of rutin on spinal cord cells. This observation was in line 
with previous reports indicating that rutin alleviated prion peptide-
induced cell death by inhibiting caspase-3 activity in dopaminergic 
and hippocampal neurons [58, 59]. Furthermore, it has been 
revealed that rutin pretreatment significantly attenuates H2O2-
induced apoptosis in HUVEC cells. Additionally, treatment with 
rutin reduced p53 expression, a protein involved in activation of 
DNA repair mechanisms and induction of apoptosis in response to 
DNA damage. Rutin administration has been found to attenuate 
ischaemic neural apoptosis by reducing p53 expression and lipid 
peroxidation in addition to upregulating endogenous antioxidant 
defence enzymatic activity [60]. These results are corroborated 
by a study conducted on the effect of rutin on sevoflurane- and 
propofol-induced neurotoxicity which concluded that rutin 
treatment was associated with a reduction in neuroapoptosis 
[61]. There is experimental evidence that rutin reduces apoptotic 
cells in ischaemic-reperfusion-induced apoptosis in both in vivo 
and in vitro models as well as in doxorubicin- and pirarubicin-
induced cardiotoxicity by suppressing caspase-3, -7 and -9 protein 
expression [62, 63]. Caspase protein downregulation is correlation 
with an increase in Bcl-2 and a decrease in Bax protein expression 
[64, 65]. This suggests that rutin may prevent apoptosis via the 
Bcl-2 regulated apoptotic pathway, but the exact mechanisms 
underlying rutin’s ability to modulate Bcl-2, Bax and caspase 
proteins are not yet fully elucidated.
Rutin as an anti inflammatory agent
Targeting neuroinflammation is a focus for AD therapy and rutin’s 
anti-inflammatory properties may in part explain its efficacy in 
AD pathology. Rutin has anti-inflammatory properties, which 
are related to the inhibition of NFβB (nuclear factor kappa 
light chain enhancer of activated B cells), and NFβB-dependent 
pro-inflammatory cytokines [66]. In a carfilzomib-induced 
cardiotoxicity rat model, rutin pre-treatment using doses of 20 
and 40 mg/kg caused a marked downregulation of NF-βB mRNA 
expression by increasing the expression of its inhibitory protein, 
IβB-β thus reducing the expression of numerous pro-inflammatory 
cytokines such as interleukin-6 (IL-6), C-reactive protein 
(CRP) and TNF-β [67]. Studies revealed that rutin suppresses 
phosphorylation of NFβB by inhibition of MAPK in lung tissue, 
in addition to decreasing the expression and cytoplasmic relocation 
of NFβB [68].
Rutin has been shown to exert anti-inflammatory effects in 
UVB-irradiated mouse skin by inhibiting COX-2 and iNOS 
expression via suppression of p38/MAPK [69]. Rutin regulates 
liver inflammation and fibrogenesis by regulating TLR4 and 
P2X7r [70]. In diabetic cardiomyopathic rats, rutin (50 mg/
kg/d) introduced post-diabetically and administered orally 
for 24 days reduced the expression of TNF-β and CRP. Pre-
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treatment with rutin at 100 mg/kg/day for 8 days in sepsis-
induced cardiac injury in mice was found to attenuate TNF-β, 
IL-6 levels and cardiac inflammation. Furthermore, rutin may 
have the potential to inhibit proinflammatory TNF-β and IL-1β 
release from monocytes [71].  Rutin inhibited high mobility group 
box 1 (HMGB1) release, down-regulated HMGB1-dependent 
inflammatory responses in human endothelial cells, and inhibited 
HMGB1-mediated hyperpermeability and leukocyte migration 
in mice [72]. HMGB1 protein acts as a late mediator of severe 
vascular inflammatory conditions. Another study was carried out 
to determine the immunomodulatory effect of rutin, catechin, 
and hesperidin on macrophage function. This study showed that 
rutin, catechin, and hesperidin possessed immunomodulatory 
activity by promoting macrophage proliferation and suppressing 
lipopolysaccharide (LPS) stimulated TNF-β, IL-1β, IL-6 and NO 
levels in rat macrophages [73].
There is also evidence of rutin’s anti-allergic inflammatory effects 
which may protect against allergic rhinitis. Rutin also demonstrates 
the ability to suppress chemokines (ICAM-1 and MIP-2), 
inflammatory cytokines and the activation of caspase-1. Topical 
administration of rutin inhibited serum histamine and mast 
cell infiltration into a mouse ear model of atopic dermatitis and 
allergic contact dermatitis (ACD). In addition, rutin suppressed 
ACD based on ear thickness and lymphocyte proliferation, 
inhibited serum IgG2a levels, and downregulated the expression 
of interferon INF-β, and IL-4, IL-5, IL-10, IL17 and TNF-β in an 
ACD ear model [74].
Alzheimer’s disease (AD) pathology and amyloid β toxicity
AD can be characterised as either late-onset (sporadic) or early-
onset (familial). Sporadic AD, which occurs in those aged 65 and 
over, is the most common subset of AD and accounts for 95% of 
AD cases. The remaining 5% of cases are classified as familial AD. 
Patients can exhibit symptoms of familial AD as early as 30 years 
of age and it is theorised that individuals who develop familial 
AD have inherited a dominant gene responsible for accelerating 
the disease [75]. Characterised as a progressive neurodegenerative 
disease, symptoms of AD gradually become more severe over 
time. It usually presents in three main stages. Early symptoms 
include forgetting recent events, forgetting the names of objects 
and regularly repeating questions or conversations. Symptoms 
occurring in the medial stage of the disease include increased 
confusion and disorientation, delusions and repetitive behaviour. 
As the disease progresses, the end stage symptoms include difficulty 
swallowing, considerable weight loss and difficulty moving.
AD has been characterised by neuronal atrophy of brain tissue. 
AD is associated with an abnormal accumulation and clearance 
of Aβ and tau proteins in the brain. The aggregation of soluble 
β amyloid into fibrillary deposits is the pathological hallmark 
of the disease. Aβ discovery and accumulation in brain resulted 
in the formulation of the “Amyloid Cascade Hypothesis” which 
states that Aβ deposition results in the formation of neurofibrillary 
tangles, neuronal cell death and dementia [76]. The amyloid 
cascade hypothesis proposes that Aβ accumulation in the brain 
is the first pathological event in AD [Figure 3] [77]. There are 2 
main forms of Aβ deposited in the parenchyma: Aβ40 and Aβ42 
which differ depending on whether the C terminus of Aβ ends at 
the 40th or 42nd amino acid. Aβ42 deposition predominates in 
AD patients; immunocytochemical probing revealed that all senile 
plaques in the AD cortex were Aβ42-positive whilst only one third 
were Aβ40-positive. There was a strong correlation between Aβ40 
and mature plaques whereas diffuse plaques were positive for Aβ42 
and negative for Aβ40 [78]. Aβ is a cleaved product of the Aβ 
precursor protein (APP) via proteolysis by β-secretase (BACE1) and 
β‐secretase [79]. In AD, excessive accumulation of Aβ monomers 
results in their assembly into soluble, diffusible oligomers e.g. 
Aβ dimers which directly induce tau hyperphosphorylation and 
neurite degeneration [80]. When the oligomers reach a critical 
concentration, they form 2 major insoluble lesions: extracellular 
neuritic plaques (NPs) and intracellular neurofibrillary tangles 
(NFTs). NFTs are composed of hyperphosphorylated tau which 
disrupts microtubules and impairs axonal transport.
Figure 3: Amyloid β toxicity
A β 
aggregation induces neurotoxicity, oxidative stress and neuro-
inflammation [81]. Previous research using tissue cultures 
demonstrates the toxic effects of Aβ fibrils to neurons as cell death 
occurred within 24 hrs of ββ exposure. The mechanism of  cell 
death may be due to apoptosis triggered by the oxidative effects of 
Aβ [82]. There is also evidence of the differing relative toxicities 
of intracellular and extracellular Aβ; intracellular injection of 
Aβ42 results in neuronal death and intracellular ββ is seen in early 
AD [83]. Research revealed that the Aβ42 fragments are more 
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susceptible to aggregation than the more predominant but less 
active Aβ40 fragment, and an increase in the cerebrospinal fluid 
Aβ42:Aβ40 ratio is also associated with increased neurotoxicity 
[84].
Amyloid β toxicity. An equilibrium between several species 
of extracellular and intracellular Aβ, including monomeric, 
oligomeric, and fibrillar forms, causes toxicity through several 
mechanisms including microglial infiltration, the generation of 
reactive oxygen species, and synaptic damage. Neurofibrillary 
tangles are generated by Aβ-induced tau phosphorylation and 
cleavage. Enzymes activated directly by extracellular Aβ include 
GSK3β, Cdk5, and multiple caspases, which activate tau cleavage 
and phosphorylation among their many deleterious effects.
Metal ions are required in the brain for a number of important 
activities including the neuronal activity within the synapses and 
metalloproteins cellular processes [85]. However, there is evidence 
suggesting that metals in and around the amyloid plaques (e.g. 
copper (Cu), zinc (Zn) and iron (Fe)), play an significant role in 
the pathogenesis of AD [86]. Copper enhances amyloid precursor 
protein (APP)  dimerization and increases the release of extracellular 
Aβ42 [87]. Both APP and Aβ have strong Cu-reductase activity, 
producing Cu+ from Cu2+ with hydrogen peroxide generated as 
by-product [88]. Aβ has some metal-binding sites on its first 15 
amino acids, constituted by the histidines 6, 13, and 14 and the 
tyrosine residue at position 10, all of which have well-known and 
potent metal-binding sites, particularly for Cu2+ [89]. The ββ 
possesses the ability to reduce Cu2+ and Fe3+ towards a nearby 
affinity to the best metallic Cu+ and Fe2+, respectively. Molecular 
oxygen can react with reduced metals thus generating a superoxide 
anion, which in turn combines with two hydrogen atoms to form 
hydrogen peroxide that may later react with another reduced 
metallic ion and then forming the hydroxyl radical by the Fenton 
reaction. The Aβ in its radical form can extract protons from the 
neighbouring lipids or proteins, thus generating lipid peroxides 
and carbonyls, respectively [90]. There is experimental evidence 
supporting the theory that metals play a role in the toxicity of Aβ 
as their entire withdrawal from the reacting medium or the use 
deferoxamine resulted in significantly lowered ββ toxicity levels 
in cellular cultures [91, 92]. Increased expression of the divalent 
metal transporter 1 (DMT1) in the senile plaques of AD patients 
has been demonstrated, in APP/SS1 transgenic mice, and even 
in cellular lines overexpressing APP. It was suggested that such 
impairments in iron homeostasis could contribute to an increase 
in oxidative stress caused by Aβ [93].  
Palop and Mucke (2010) theorised that Aβ reduces excitatory 
transmission across synapses by reducing glutamatergic synaptic 
transmission. Increased levels of Aβ is thought to inhibit neuronal 
excitability via a negative feedback loop. Loss in excitatory 
transmission over a prolonged period is thought to cause synaptic 
loss and a decline in neurological function.  Aβ1–42 binds 
with a significantly greater affinity to the β7-nicotinic receptors 
than Aβ1–40. It is proposed that this differential binding may 
play a significant role in the internalisation and accumulation 
of Aβ in cholinergic neurons, a theory that is supported by 
experiments which have successfully blocked the internalisation 
and accumulation of Aβ1–42 using β7 receptor antagonists. 
Since Aβ1-42 predominantly accumulates in neurons that have 
β7-nicotinic receptors, it has been suggested that the presence of 
this receptor may be an underlying factor for the selective cellular 
toxicity shown by Aβ in the brain of AD patients [94]. Due to 
susceptibility to aggregation and potent neurotoxicity of amyloid 
fibrils in the brain, the strategy of inhibiting Aβ42 aggregation 
has long been considered a focus for effective disease modifying 
therapy for AD [95]. In healthy individuals, Aβ production and 
clearance is rapid, which is estimated at around ~7.6% and 8.3% 
respectively, of the total volume of Aβ produced per hour [96]. 
Aβ has been found in membranous intracellular structures such 
as the endoplasmic reticulum, the Golgi system, lysosomes, 
endosomes, and in the mitochondria’s inner membrane or matrix 
[97]. Nevertheless, the origin of mitochondrial Aβ is uncertain. APP 
is believed to be located in the mitochondrial external membrane, 
but to date, only β-secretase enzymes have been identified in the 
inner mitochondrial membrane and enzymes with β secretase 
activity have not yet been found. An alternative explanation is that 
Aβ peptide is elaborated on a separate site and then moved inside the 
mitochondria . In the presence of calcium, Aβ can create transition 
pores in the mitochondrial membrane through which cytochrome 
C can be released and initiate, pro-apoptotic signalling pathways. 
Aβ can directly inhibit the generation of mitochondrial ATP, and 
affect the correct functioning of the β-subunit of ATP synthase 
[98]. Cellular exposure to Aβ generates an increase in intracellular 
calcium, which is associated with cell damage and cell death [99]. 
However, the mechanism by which this increase in intracellular 
calcium occurs is not well understood. A variety of Aβ-activated 
receptors and channels are thought to be involved, but it is also 
known that Aβ can directly interplay with the lipid components of 
the cell membrane, forming pores or ionic channels that help Ca2+ 
to enter into the cell. Pharmacological blockage of these pores or 
ionic channels was found to attenuate Ca2+ entering into the cell 
and neuronal damage. Without altering enzymatic mitochondrial 
machinery, Aβ administration in sub-toxic doses over a prolonged 
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period, inhibits the transportation of nuclear proteins to the 
mitochondria thus impairing mitochondrial membrane potential 
and the production of ROS [100]. The activation of enzymes 
such as NOX, xanthine oxidase, and A2 phospholipases (in 
both cytosolic and calcium-dependent forms) is involved in the 
mitochondrial dysfunction and the production of ROS mediated 
by Aβ. When such enzymes are pharmacologically blocked, ROS 
production and mitochondrial dysfunction by Aβ are significantly 
reduced.
Applications of rutin in AD
Effects of rutin on Aβ induced toxicity
Rutin can inhibit aggregation and cytotoxicity of Aβ inhibit damage 
of mitochondrial, decrease the production of ROS [101]. Several 
studies demonstrate that rutin can interfere with aggregation and 
toxicity of Aβ, inhibit oxidative stress induced by Aβ, reduce Aβ42 
levels in mutant human APP overexpressing cells, and reduce senile 
plaques in the brain of APP transgenic mice [102, 103]. Research 
revealed that polyphenol compounds exhibit inhibitory effects on 
Aβ42 aggregation by binding hydrophobic β-sheet channels with 
their aromatic structure and simultaneously disturb the formation 
of Aβ hydrogen bonds through the action of hydroxyls as electron 
donors [104, 105, 106, & 107]. Rutin is composed chemically 
of an aromatic core with polyhydroxyl groups which may be 
responsible for its aforementioned mechanisms of action [108]. 
Rutin was found to reduce the Aβ42-induced cytotoxicity by 
interacting with Aβ to modify the structure of Aβ oligomers and 
inhibit their cytotoxicity. Rutin was found to decrease Aβ25–35 
fibril formation and accumulation in in vitro, thereby inhibiting 
neurotoxicity, as well as decreasing Aβ plaque aggregation, NO 
production, pro-inflammatory cytokine production and oxidative 
stress in in vivo.
Neuroprotective effects of rutin
Rutin exerts its neuroprotective potentials by interacting with 
critical protein and lipid kinase signalling cascades (such as PI3K/
Akt, protein kinase C and MAPK) in the brain which results in 
the inhibition of apoptosis triggered by Aβ and promotes neuronal 
survival and synaptic plasticity. It has beneficial effects on the 
vascular system leading to changes in cerebrovascular blood flow 
by angiogenesis and neurogenesis. Oral rutin administration may 
protect the CA3 region of the hippocampus in rats and have 
an impact on their behaviour, decreasing memory impairment 
due to trimethylin toxicity [109, 110, & 111]. Rutin attenuates 
age-related memory deficit in mice [112]. Rutin significantly 
attenuated memory deficit in AD transgenic mice, decreased 
oligomer Aβ level, increased SOD activity and GSH/GSSG ratio, 
reduced GSSG and MDA levels, down regulated microgliosis and 
astrocytosis, and decreased IL –Iβ and IL-6 levels in brain. Rutin 
improved memory and behaviour in open field, elevated plus and 
Y- mazes tests, possibly due to the reduction in neuroapoptosis in 
sevoflurane or propofol exposed neonatal mice. Rutin prevented 
cognitive deficits and morphological changes in the hippocampus; 
and attenuated lipid peroxidation, COX-2, GFAP, IL-8, iNOS and 
NFβB in a rat model of sporadic dementia [113]. It also prevented 
memory deficits and ameliorated oxidative stress, apoptosis and 
neurite growth in a rat model for cognitive dysfunction [114]. 
Rutin exerted an antidepressant-like effect, potentially facilitated 
by its NMDA receptor-mediated neuroprotective action on the 
hippocampus [115]. Rutin pre-treatment reduces infarct size 
and neurological deficits in rats following middle cerebral artery 
occlusion and protects the antioxidant content of enzymes in 
the brain [116, 117]. Rutin protected against neurodegenerative 
effects of prion accumulation by increasing the production of 
neurotrophic factors and inhibiting apoptotic pathway activation 
[118]. Rutin also has potential anticonvulsant and antioxidant 
activities against oxidative stress in kainic acid-induced seizures in 
mice [119]. 
Additionally, rutin is important in the promotion of neural crest 
cell survival in CNS. The neural crest is a progenitor comprising of 
neural and mesenchymal potentials. When applied to trunk neural 
crest cells, rutin augmented their viability without altering cell 
differentiation and proliferation, potentially due to the modulation 
of ERK2 and PI3K pathways [120]. It is also revealed that rutin 
has a sedative effect. Rutin, given via the intraperitoneal route 
caused a depressant action on the CNS, potentially medicated 
by the GABAA receptor [121].In a study on haloperidol-induced 
orofacial dyskinesia, rutin treatment reversed behavioural changes 
such as orofacial dyskinesia movements, stereotypic rearing, 
locomotor activity, and percent retention coupled with the 
restoration of biochemical and neurochemical parameters [122].
Inhibition of neuroinflammation by rutin
Neuroinflammation is a complex response to brain injury 
involving the activation of glia, release of inflammatory mediators, 
such as cytokines and chemokines, and generation of ROS [123]. 
Inflammatory responses in the brain are associated with increased 
levels of prostaglandins (PGs), particularly PGE2. Elevated PGE2 
and inflammatory mediators are characteristic of the ageing brain. 
An increased state of neuroinflammation renders the aged brain 
more susceptible to the disruptive effects of both intrinsic and 
extrinsic factors such as infection, diseases toxicants, or stress. 
AD pathology has been linked to microglial secretion of 
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proinflammatory cytokines, PGs, ROS and NOS thereby resulting 
in chronic stress, and if sustained over a prolonged period, even 
neuronal death [124, 125]. Neuroinflammation associated 
with AD can be inhibited by nonsteroidal anti-inflammatory 
drugs (NSAIDS) via maintaining Ca2+ homeostasis, targeting 
β-secretase, Rho-GTPases and PPAR [126]. The NSAIDs 
ibuprofen, indomethacin and flurbiprofen were found to decrease 
ββ(1-42) peptide toxicity in both in vivo and in vitro models 
through the inhibition of COX [128].
Rutin administration resulted in a reduction in neuroinflammation 
in rat model of AD and produced neuroprotective effects in 
dexamethasone-treated mice [128]. There is evidence that rutin 
decreases TNF-β and IL-1β generation in microglia in a rat 
model of spinal cord injury [129]. Rutin inhibited apoptosis 
by decreasing oxidative stress, Bax/Bcl-2, caspase-3 and -9 and 
c-Jun and p38 phosphorylation in Dopaminergic cells exposed 
to LPS [130]. Additional pharmacological mechanisms of rutin 
in the literature include the inhibition of Aβ aggregation and 
cytotoxicity, the prevention of mitochondrial damage, reduction 
in pro-inflammatory cytokine (TNF-β and IL-1) production, and 
an increase in the levels of CAT and SOD. Sodium rutin was found 
to attenuate neuroinflammation, enhance microglial-mediated Aβ 
clearance, ameliorate synaptic plasticity impairment and reverse 
spatial learning and memory deficits in two mouse models of AD 
[131].
Conclusion 
Rutin is a flavonoid with distinguished pharmacological effects 
and promising therapeutic potential. The ability of rutin to exert 
its neuroprotective effects could be ascribed to its antioxidant as 
well as antiapoptotic and anti-inflammatory activities. Rutin can 
inhibit aggregation and cytotoxicity of Aβ; inhibit mitochondrial 
damage, decrease the production of ROS, MDA, GSSG, NO, 
iNOS and proinflammatory cytokines; increase SOD, GPx, CAT 
activity; and upregulate GSH. The ability of rutin to provide 
neuroprotection against pathological insult offers hope in its 
utilization and development as a safe and effective neurotherapeutic 
agent for AD. However, its low bioavailability owing to high 
metabolism, poor absorption, and rapid excretion makes its 
potential use as a therapeutic agent restricted. There is a paucity 
of clinical trial evidence exploring the efficacy of rutin in AD 
patients. The focus of future studies of rutin as a neuroprotective 
agent should be to improve its bioavailability, developing related 
molecules with greater gut and brain penetrability, a major barrier 
which has impeded the development of rutin-derived drugs.
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